CL2024002605A1 - Proteína de fusión de insulina - Google Patents

Proteína de fusión de insulina

Info

Publication number
CL2024002605A1
CL2024002605A1 CL2024002605A CL2024002605A CL2024002605A1 CL 2024002605 A1 CL2024002605 A1 CL 2024002605A1 CL 2024002605 A CL2024002605 A CL 2024002605A CL 2024002605 A CL2024002605 A CL 2024002605A CL 2024002605 A1 CL2024002605 A1 CL 2024002605A1
Authority
CL
Chile
Prior art keywords
fusion protein
insulin fusion
insulin
canine
subject
Prior art date
Application number
CL2024002605A
Other languages
English (en)
Spanish (es)
Inventor
J Busfield Samantha
J Wilson Matthew
Original Assignee
Scout Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scout Bio Inc filed Critical Scout Bio Inc
Publication of CL2024002605A1 publication Critical patent/CL2024002605A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2024002605A 2022-03-01 2024-08-30 Proteína de fusión de insulina CL2024002605A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263315296P 2022-03-01 2022-03-01

Publications (1)

Publication Number Publication Date
CL2024002605A1 true CL2024002605A1 (es) 2025-07-11

Family

ID=87884362

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002605A CL2024002605A1 (es) 2022-03-01 2024-08-30 Proteína de fusión de insulina

Country Status (11)

Country Link
US (1) US20250188144A1 (https=)
EP (1) EP4486796A4 (https=)
JP (1) JP2025507929A (https=)
KR (1) KR20240167718A (https=)
CN (1) CN119562965A (https=)
AU (1) AU2023228668A1 (https=)
CA (1) CA3245376A1 (https=)
CL (1) CL2024002605A1 (https=)
IL (1) IL315354A (https=)
MX (1) MX2024010693A (https=)
WO (1) WO2023168288A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173090B (zh) * 2025-05-21 2025-07-29 华中农业大学 猫血清白蛋白突变体、及其cho细胞表达方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2676932C (en) * 2007-02-01 2015-11-24 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
BR112014015156A2 (pt) * 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein

Also Published As

Publication number Publication date
JP2025507929A (ja) 2025-03-21
CA3245376A1 (en) 2023-09-07
US20250188144A1 (en) 2025-06-12
KR20240167718A (ko) 2024-11-27
WO2023168288A2 (en) 2023-09-07
AU2023228668A1 (en) 2024-09-19
WO2023168288A3 (en) 2023-09-28
MX2024010693A (es) 2024-12-06
EP4486796A4 (en) 2026-03-04
IL315354A (en) 2024-11-01
CN119562965A (zh) 2025-03-04
EP4486796A2 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
CL2024002605A1 (es) Proteína de fusión de insulina
CR8932A (es) Composicion de anticuerpo her2
CL2024002586A1 (es) Genoma de vector viral que codifica una proteina de fusion de insulina.
CR11594A (es) Preparacion de solucion que contiene anticuerpos en una alta concentracion
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
PE20121496A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
CL2012001232A1 (es) Composicion farmaceutica liquida que comprende un agonista de glp-1: despro36 exendina-4-(1-39)-lys6-nh2, insulina humana gly(a21)-arg(b31)-arg(b32), o sales de ellos, l-metionina y opcionalmente un excipiente; combinacion; kit; metodo de preparacion; uso para tratar la diabetes.
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR061242A1 (es) Polipeptidos de factor de crecimiento de tipo insulina estabilizada
CO6290624A2 (es) Composición oral que contiene amino ácidos, fluoruro y un tampón, y método de preparación de la misma
AR065145A1 (es) Metodo para reducir la inflamacion y el estres en mamiferos
PE20160781A1 (es) Formulaciones de insulina de accion prolongada
AR070276A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion.
ES2078521T3 (es) Nuevos conjugados de proteina-polication.
AR117640A1 (es) Compuestos de 2,6-diaminopiridina como inhibidores de khk
CN204837511U (zh) 牛羊多功能项圈
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
ECSP23024034A (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
PA8588901A1 (es) Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
AR069892A1 (es) Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion.
AR124883A1 (es) Alimento para ganado
CL2025001479A1 (es) Plantas y células vegetales modificadas
HN1998000141A (es) Composicion farmaceutica antimastitica a base de extractos de origen natural y procedimientom para fabricarla.
JPH0761957B2 (ja) イオン導入法により活性剤の皮膚濃度を高める為の組成物
PE20242347A1 (es) Materiales y metodos de proteinas de union a il-1 beta